Publication & Citation Trends
Publications
0 total
TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer OA
Cited by 9
Semantic Scholar
Trastuzumab-Resistant HER2+ Breast Cancer Cells Retain Sensitivity to Poly (ADP-Ribose) Polymerase (PARP) Inhibition OA
Cited by 13
Semantic Scholar
The expression of class II major histocompatibility molecules on breast tumors delays T cell exhaustion, expands the T cell repertoire and slows tumor growth OA
Cited by 2
Semantic Scholar
PO-487 Prognosis of triple negative breast cancer is associated with MHC II genes OA
Cited by 0
Semantic Scholar
Abstract 4030: Epigenetic induction of MHC-II pathway expression in murine ovarian cancer cell line
Cited by 0
Semantic Scholar
Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes OA
Cited by 138
Semantic Scholar
Abstract 1461: MHCII-expressing breast cancer cells can induce anti-tumor immune response
Cited by 0
Semantic Scholar
PARP1 and phospho-p65 protein expression is increased in human HER2-positive breast cancers OA
Cited by 23
Semantic Scholar
Research Topics
Monoclonal and Polyclonal Antibodies Research
(65)
Radiopharmaceutical Chemistry and Applications
(54)
Immunotherapy and Immune Responses
(39)
PARP inhibition in cancer therapy
(39)
Lymphoma Diagnosis and Treatment
(26)
Affiliations
Southern Research Institute
Northwestern University
Gynecologic Oncology Group
Simpson University
Greenwich Hospital